Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock, par value $0.0001 per share, from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks